1
Biomarker Validation Following Sargramostim Treatment in Parkinson’s Disease
Condition(s):Parkinson’s Disease and ParkinsonismLast Updated:January 10, 2023Not yet recruiting
Sargramostim, Leukine: 755 Clinical Trials, Page 1 of 76
Hide Studies Not Open or Pending
2
Biomarker Assessments of Leukine During Treatment of Parkinson’s Disease
Condition(s):Parkinson DiseaseLast Updated:October 21, 2022Active, not recruiting
3
Study of Sargramostim in Patients With COVID-19
Condition(s):COVID-19; SARS-CoV-2Last Updated:February 18, 2022Completed
4
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
Condition(s):Solid Tumor; Solid Tumor, AdultLast Updated:December 2, 2022Suspended
5
Sargramostim Use in COVID-19 to Recover Patient Health
Condition(s):Covid19; SARS-CoV InfectionLast Updated:February 6, 2023Completed
6
Sargramostim for Myeloid Dendritic Cell Deficiency
Condition(s):Kidney Diseases; Kidney TransplantLast Updated:December 31, 2018Terminated
7
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Condition(s):Autoimmune Pulmonary Alveolar ProteinosisLast Updated:August 3, 2021Completed
8
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer’s Disease
Condition(s):Alzheimer DiseaseLast Updated:July 21, 2022Recruiting
9
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Condition(s):COVID-19Last Updated:November 16, 2022Completed
10
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Condition(s):Acute Myeloid Leukemia NOSLast Updated:April 20, 2017Withdrawn